مباشر
FierceBiotechReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection10x Genomics Blog10x Genomics debuts Atera, a new platform to redefine how biology is measured and understood at AACR 2026 - SelectScienceIlluminaClinical Genomic Market: Growth and Outlook Driven by Illumina, - openPR.comThermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships - simplywall.stCuriosis Inc.Working capital per share of Curiosis, Inc. – KRX:494120 - TradingViewWatersWaters Corporation Schedules First Quarter 2026 Earnings Conference Call - ChartMillLonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract focus strong enough to unlock new ups - AD HOC NEWSCellB cell deficiency limits exercise capacity by remodeling liver glutamate metabolismCellA phytoscreen identifies a garlic compound as a deterrent of mating and egg laying in <em>Drosophila</em> and mosquitoesCellp53 safeguards chemical reprogramming of human somatic cells toward pluripotencyCell2'3'-cGAMP-induced membrane shearing promotes broad antiphage immunityCellGut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade
Endpoints News ٣٠ مارس ٢٠٢٦

Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?

Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete?

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.